{"slug":"bpc-157-ibd-crohns-colitis","verification":{"valid":true,"entries":28,"head":"749d85c59d1f91b3848cc191b8562a294feb1155d5127805649783841e4ed1fa"},"energy":{"passes":28,"tokens_in":13757,"tokens_out":2101,"tokens_total":15858,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":12,"system/audit-repair":8,"kimi/moonshot-v1-8k":1,"gemini/gemini-2.5-flash":1,"repair":1,"fill-slots":2,"owner":1},"head":"749d85c59d1f91b3848cc191b8562a294feb1155d5127805649783841e4ed1fa"},"provenance":[{"ts":"2026-06-29T08:48:06.723Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: BPC-157 for IBD, Crohn's Disease, and Colitis\n\nAudience: 3M diagnosed in the US. The problem: immune system attacks gut lining; current treatments are immunosuppressants/biologics that suppress response but don't repair lining. Why BPC-157 maps: repairs gut lining and reduces inflammation without immune suppression. Novelty: 8/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"bpc-157-ibd-crohns-colitis-evidence-review\",\n  \"title\": \"BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status\",\n  \"body\": \"## Overview of IBD Pathology\\nInflammatory bowel diseases including Crohn's disease and ulcerative colitis involve immune-mediated damage to the intestinal lining, leading to inflammation, ulceration, and impaired barrier function. Standard approaches often focus on modulating immune responses.\\n\\n## BPC-157 Mechanism in Gut Tissue\\nBPC-157 is a stable gastric pentadecapeptide derived from a gastric juice protein. Preclinical studies indicate it promotes local angiogenesis and cytoprotection in gastrointestinal tissues.\\n\\n## Preclinical Evidence in Colitis and IBD Models\\nMultiple rat studies demonstrate BPC-157 accelerates healing of cysteamine-induced colitis, reduces lesion severity, and supports anastomosis repair without systemic immune suppression. One study combined colitis with a multiple sclerosis model and reported concurrent improvement in both gut and neural damage.\\n\\n## Human Trial Data Status\\nBPC-157 was described as safe in early-phase clinical trials for IBD (PL-10, PLD-116, PL14736) conducted by Pliva, with references in papers from 2006–2012. No large-scale randomized controlled human trials or recent safety/efficacy publications are available in indexed literature.\\n\\n## Distinction from Immunosuppressive Approaches\\nAnimal data emphasize direct tissue repair and mucosal protection rather than broad immune suppression. This framing appears in cytoprotective models of NSAID injury, fistulas, and colitis.\\n\\n## Limitations and Data Gaps\\nAll robust efficacy signals derive from rodent and in vitro models. Human evidence remains limited to historical phase II mentions without published outcome data. No approved regulatory status exists for these indications.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"BPC-157 accelerates healing of cysteamine-ind","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"fe1c57dc8a4ae2c52f643f2946342489af85172b8d9cdc928495c97f30ad8327"},{"ts":"2026-06-29T10:24:06.974Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe1c57dc8a4ae2c52f643f2946342489af85172b8d9cdc928495c97f30ad8327","hash":"dafc9baf9480f463c75787398908c10b220b1006667fb06c7d90602e0fbcdc5c"},{"ts":"2026-06-29T10:24:29.291Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dafc9baf9480f463c75787398908c10b220b1006667fb06c7d90602e0fbcdc5c","hash":"b1bba413c87e957e3d73e27661eced2f679110f42de4543b7f37bff1239e5b0a"},{"ts":"2026-06-29T10:24:59.156Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b1bba413c87e957e3d73e27661eced2f679110f42de4543b7f37bff1239e5b0a","hash":"b3c960902ee4b9d7ff48a50f345d21bf1b2dc02c78731e7fd17474426e678e30"},{"ts":"2026-06-29T10:25:21.910Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b3c960902ee4b9d7ff48a50f345d21bf1b2dc02c78731e7fd17474426e678e30","hash":"8d56c7c240452f0bcedb19db96deb39dd5f070bebba6691747e6f7409b37fe17"},{"ts":"2026-06-29T12:47:53.583Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8d56c7c240452f0bcedb19db96deb39dd5f070bebba6691747e6f7409b37fe17","hash":"38859ca7fe93da62010b2de037bb4784c468b2a6e30595c9c7e319fe7c26a7c7"},{"ts":"2026-06-29T12:47:54.129Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c25","response":"BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"38859ca7fe93da62010b2de037bb4784c468b2a6e30595c9c7e319fe7c26a7c7","hash":"dd67b87d9bac520d1ea5e17cab27546576c460cb0c88fbbbb11530f98c6c24ed"},{"ts":"2026-06-29T12:47:54.191Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c26","response":"Per this ledger on BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status: 14 scientific and 10 anecdotal sources are catalogued; 6 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dd67b87d9bac520d1ea5e17cab27546576c460cb0c88fbbbb11530f98c6c24ed","hash":"8ffe09fb21d56a6824840d59e111fa15eecc2c3f56805461fd4fe548554645a9"},{"ts":"2026-06-29T12:47:54.292Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c27","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8ffe09fb21d56a6824840d59e111fa15eecc2c3f56805461fd4fe548554645a9","hash":"f78f964d5226861353d5d441b0df15fddfe3c51db9988a2a7a59d3f1ecadf8d6"},{"ts":"2026-06-29T12:47:54.414Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c28","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f78f964d5226861353d5d441b0df15fddfe3c51db9988a2a7a59d3f1ecadf8d6","hash":"4d38ec152a11cd40f5750c4d04d7d1824c3fe86bb3ca1f407a033fb9a3b8b093"},{"ts":"2026-06-29T12:47:55.073Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4d38ec152a11cd40f5750c4d04d7d1824c3fe86bb3ca1f407a033fb9a3b8b093","hash":"dc0893363b13139637018d793f5f903e5f5875316d1b565c9e7ce89acf7c2d19"},{"ts":"2026-06-29T13:24:09.181Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dc0893363b13139637018d793f5f903e5f5875316d1b565c9e7ce89acf7c2d19","hash":"97e39c529ca94b9c8e948e8155a7674a6e3e46987cbbcf45e3634aa3a5755f17"},{"ts":"2026-06-29T13:24:10.419Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"97e39c529ca94b9c8e948e8155a7674a6e3e46987cbbcf45e3634aa3a5755f17","hash":"20cca55981c01d65456633c07b44685656e9f8cf196a4c42423dfbfc535f5b26"},{"ts":"2026-06-29T13:32:45.835Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"I am adding explicit gaps in knowledge and naming anecdotal claimants as instructed, while not inventing any new URLs or medical advice.","tokens_in":3200,"tokens_out":387,"cost":0,"prev":"20cca55981c01d65456633c07b44685656e9f8cf196a4c42423dfbfc535f5b26","hash":"70ebc6ee422d3ce806642a10b2a4c2cbb1070300ab3282c32456de28b42d0fbb"},{"ts":"2026-06-29T15:03:14.582Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"I am Gemini, not Grok. I added three tier-honest claims to address gaps in the ledger, specifically focusing on 'what_is_unknown' regarding long-term safety and clinical application, and 'who_claims_what' by incorporating a medical professional's discussion. I also challenged a claim where the cited source was misattributed, clarifying the nature of the evidence.","tokens_in":2925,"tokens_out":632,"cost":0,"prev":"70ebc6ee422d3ce806642a10b2a4c2cbb1070300ab3282c32456de28b42d0fbb","hash":"5232cfb95500f8b9a2998a71ce83e54daf84b8ab0e05f9602a9f1734a29471a6"},{"ts":"2026-06-29T15:05:54.386Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"## Regeneration vs degeneration — where this fits\nThe body breaks down tissue and builds it back at the same time. IBD, Crohn's, and colitis persist when breakdown outpaces repair in the gut lining. Most drugs reduce inflammation signals without rebuilding the damaged wall. BPC-157 is studied for a repair path: new blood vessels at the injury site bring cells and nutrients that can close ulcers and restore tissue.\n\n## What it is\nBPC-157 is a short chain of amino acids first found in human stomach fluid. Researchers test it in rat models of gut injury to measure healing speed and blood flow changes.\n\n## How it works\nStep 1: Injury cuts blood supply and raises oxidative stress.  \nStep 2: BPC-157 appears to activate the nitric oxide system.  \nStep 3: Nitric oxide widens vessels and opens collateral routes.  \nStep 4: More blood reaches the area, carrying repair cells and oxygen.  \nStep 5: Ulcer size shrinks and tissue continuity returns in the tested models.\n\n## Why it would work (logic chain)\nIf new blood supply reaches damaged gut faster, then oxygen and cells arrive before further breakdown occurs. If cells arrive before breakdown wins, then ulcers close and symptoms tied to open tissue drop. The chain is therefore blood flow first, tissue closure second, symptom change third.\n\n## Why people take it\nPeople with IBD seek options that target tissue repair rather than only symptom suppression. They read rat studies on colitis healing and look for compounds reported to act on the same pathway.\n\n## How many people take it\nThe ledger lists 8 Reddit posts and 1 X post that mention use. No population count exists in the sources. The number of people taking it is unknown.\n\n## Evidence inventory\nSources total 24.  \nStudies catalogued: 14.  \nReddit posts: 8.  \nX posts: 1.  \nOther anecdote sources: 1.  \nHuman claims: 2.  \nPreclinical claims: 9.  \nAnecdotal claims: 11.  \nAnimal studies: 5 rat colitis or anastomosis models.  \nHuman studies: 0 completed IBD trials with published ou","tokens_in":7632,"tokens_out":1082,"cost":0,"prev":"5232cfb95500f8b9a2998a71ce83e54daf84b8ab0e05f9602a9f1734a29471a6","hash":"5be637181945c1bf960d861154271175cc24d566f454c44b30dc7b7a3ad4b181"},{"ts":"2026-06-29T15:47:19.434Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5be637181945c1bf960d861154271175cc24d566f454c44b30dc7b7a3ad4b181","hash":"2459415c0fa5025ce0d69d2f626411d2242048c03d0f6fb82e8acea69e45900e"},{"ts":"2026-06-29T15:47:55.176Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2459415c0fa5025ce0d69d2f626411d2242048c03d0f6fb82e8acea69e45900e","hash":"b0d1a14d28b9252cb95c2903f564c360a22349649d7f09f02352f7a698375f82"},{"ts":"2026-06-29T15:48:18.667Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b0d1a14d28b9252cb95c2903f564c360a22349649d7f09f02352f7a698375f82","hash":"0e39e1baaa3c66af857cb9ba333c48ea0113ee087428ed4b89cca8310722571c"},{"ts":"2026-06-29T15:49:26.581Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0e39e1baaa3c66af857cb9ba333c48ea0113ee087428ed4b89cca8310722571c","hash":"385b3c3e7fb0bc78a3aa8d57106463755c7aad6b44b910f9abe469f767c37811"},{"ts":"2026-06-29T15:49:55.938Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"385b3c3e7fb0bc78a3aa8d57106463755c7aad6b44b910f9abe469f767c37811","hash":"24d5c8e53d9bbc16dfcf482f73519f07dae97ef36807e0b12139f1bed2837e4d"},{"ts":"2026-06-29T15:50:28.635Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"24d5c8e53d9bbc16dfcf482f73519f07dae97ef36807e0b12139f1bed2837e4d","hash":"0cc8439525f6eb06974c30063ac1563148642d3708a9ce48c8113091a53a3c04"},{"ts":"2026-06-29T17:53:30.413Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0cc8439525f6eb06974c30063ac1563148642d3708a9ce48c8113091a53a3c04","hash":"eebd5e6013d72e2f6fadbeddd074317896c1f39d5fd6243a20d9f431269aa562"},{"ts":"2026-06-29T17:54:03.747Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"eebd5e6013d72e2f6fadbeddd074317896c1f39d5fd6243a20d9f431269aa562","hash":"6163aac70cb6c616bf34897f3106f850fe8078a5ad9e1c200d4aea82c265e435"},{"ts":"2026-06-29T19:36:05.229Z","model":"repair","action":"repair","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":4,\"cycle\":4,\"adjacent\":36}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6163aac70cb6c616bf34897f3106f850fe8078a5ad9e1c200d4aea82c265e435","hash":"610cf4347c56f0fdbe12f0575913ed735132b6adff65658f75b2a67645c60c0e"},{"ts":"2026-06-29T20:50:04.208Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c73","response":"BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"610cf4347c56f0fdbe12f0575913ed735132b6adff65658f75b2a67645c60c0e","hash":"c3bd635ea9f3b1f7835f12e38973327b8b1066c2c26160d96c19dfa2efa78cba"},{"ts":"2026-06-29T20:50:06.803Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157-ibd-crohns-colitis c74","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c3bd635ea9f3b1f7835f12e38973327b8b1066c2c26160d96c19dfa2efa78cba","hash":"410ffb69889fe1430645745f9e3bb3eaefecde93c2857dd8dbd14d926517a0cf"},{"ts":"2026-07-17T02:38:36.793Z","model":"owner","action":"voxel_divide","prompt":"","input":"bpc-157-ibd-crohns-colitis","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"410ffb69889fe1430645745f9e3bb3eaefecde93c2857dd8dbd14d926517a0cf","hash":"749d85c59d1f91b3848cc191b8562a294feb1155d5127805649783841e4ed1fa"}]}